A fast-growing and highly profitable US-headquartered med-tech group has increasingly experienced tax challenges related to its policy in Europe. We were hired by the US headquarters to help the client securitize its transfer pricing model and operating margin allocations going forward. The range of services involves innovative and superior approaches to economic analysis and benchmarking, advice on economic substance and DEMPE contribution matters, and advice on the management of field tax audits in Western Europe.